Journal
CANCER CELL
Volume 23, Issue 2, Pages 139-141Publisher
CELL PRESS
DOI: 10.1016/j.ccr.2013.01.018
Keywords
-
Categories
Funding
- NCI NIH HHS [T32 CA009172, R01 CA129974] Funding Source: Medline
Ask authors/readers for more resources
ABT-199 is a new selective small molecule inhibitor of BCL-2 that appears to spare platelets while achieving potent antitumor activity. Assays that can predict the efficacy of ABT-199 in individual tumors will be critical in determining how best to incorporate this promising agent into the armamentarium of cancer therapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
